Search results
The impact of lifestyle intervention in rheumatoid arthritis
Medical Xpress· 6 hours agoNow, new work shared at the 2024 EULAR congress in Vienna is expanding on this, with data from a ...
Despite high concordance and initial translation, why do animal studies rarely lead to approvals?
FierceBiotech· 8 hours agoMore often than expected, according to a new analysis by scientists at Switzerland’s University of...
EHA 2024: AstraZeneca’s Calquence plus chemoimmunotherapy offers new standard for MCL
Pharmaceutical Technology via Yahoo Finance· 3 hours agoThe trial tested the drug in combination with chemoimmunotherapy, bendamustine and Roche/Biogen’s...
Only 1 in 20 animal studies results in treatments approved for humans
United Press International via Yahoo News· 3 days agoBenjamin Ineichen, a neurologist with the University of Zurich in Switzerland. Research tends to...
Beacon Therapeutics treats first patient with AGTC-501 in pivotal VISTA trial
Pharmaceutical Technology via Yahoo Finance· 7 hours agoAGTC-501 is currently in Phase II/III of development for retinitis in the VISTA trial (NCT04850118),...
This New Hybrid Work Study Could Help Reconcile The War Over Work From Home
Forbes· 6 days agoLeaders eager to get workers back to the office often believe it leads to things like lower worker output and an erosion of workplace culture. A randomized controlled ...
Randomized trial, meta-analysis shed new light on optimal antibiotic strategy for sepsis
Center for Infectious Disease Research and Policy· 5 days agoThe first study reports results from the Beta-Lactam Infusion Group (BLING) III trial, an...
Johnson & Johnson’s nipocalimab shows promise in Sjögren’s disease trial
Clinical Trials Arena via Yahoo Finance· 13 hours agoThis study included a Phase II dose-ranging trial for adults with moderately-to-severely active...
OA Patients Get Long-Term Benefit From Lifestyle Improvements
MedPage Today· 4 days agoTwo years after completing a 4-month program to improve eating and exercise habits in a randomized ...
EHA 2024: Brukinsa/Venclexta for CLL/SLL lacks control arm in SEQUOIA trial
Clinical Trials Arena via Yahoo Finance· 7 hours agoAt the 2024 Congress of the European Hematology Association (EHA 2024) on 14 June, preliminary...